Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.

Overview of attention for article published in JCO Precision Oncology, December 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 16 X users

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 22 X posts from 16 X users, with an upper bound of 140,105 followers.

RT @VivekSubbiah: Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or…

RT @curijoey: @IEOufficiale @LaStatale @OncoAlert https://t.co/HXi5yhYgwz

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.